Comparing the GSVA scores of immune cell signatures from ConsensusTME [24] with AXL expression in sorafenib-sensitive and sorafenib-resistant HCC samples, we observed that AXL expression was negatively correlated with immune cell signatures including T lymphocytes in sorafenib-resistant HCC samples (Fig. 2B), whereas AXL expression is positively correlated with immune cell signatures in sorafenib-sensitive HCC samples (Suppl. The gene discussed is AXL; the disease is hepatocellular carcinoma.